You are here:   Content Hub > Pharmavibe > EU issues GMP Annex 1 final revision for sterile drug products
Discover your favourite episodes effortlessly
PharmaVibe, capture the dynamics of the pharmaceutical industry
Listen and sense the heartbeat of the industry through news stories, key conferences, and in-depth interviews encompassing an array of specialties, sectors, and areas
Subscribe Now
Access more contents on Content Hub >>
Webniars
Industry Reports
Pharma Sources Insight
EPISODE 19 | 12 MIN | 30 Aug. 2022

EU issues GMP Annex 1 final revision for sterile drug products

EPISODE 19 | 12 MIN | 30 Aug. 2022
#Drug Review #R&D #Business #Policy
EU issues GMP Annex 1 final revision for sterile drug products
Play
Summary
In the last week's Chinese pharma market, the 11th indication of BeiGene’s PD-1 Tislelizumab was declared for marketing for the treatment of esophageal squamous cell carcinoma. While in the global pharma market, Johnson & Johnson’s Teclistamab was approved by the EC, making it the first BCMA/CD3 bispecific antibody approved for marketing worldwide. In addition, the EU officially released the eagerly anticipated final revision of its GMP Annex 1 for sterile drug products. Other pharma news collected in this episode covers 4 sections including drug review, R&D, business, and policy.
Timeline
1
PART1 | 01:04
The new indication of BeiGene Tislelizumab was accepted by the NMPA
2
PART2 | 01:39
The clinical trial application for Ascletis’ASC10 was approved
3
PART3 | 02:10
Shanghai Pharma's B013 injection was approved by the NMPA for Phase II clinical trials
4
PART4 | 02:42
The 4th-generation EGFR inhibitor of Qilu Pharmaceutical QLH11811 was approved for clinical use
5
PART5 | 03:35
Junshi Biosciences's anti-CD112R monoclonal antibody injection was approved by the CDE for clinical trials to treat advanced solid tumors
6
PART6 | 04:04
Tiannuo Jiancheng's monoclonal antibody targeting CCR8, CM369, was approved for clinical trials
7
PART7 | 04:38
The clinical trial application of Akeso's AK129 injection was accepted for the treatment of cancers
8
PART8 | 05:25
The clinical trial application of BavarianNordic and Nuance's MVA-BNRSV vaccine was accepted for the prevention of RSV infection
9
PART9 | 05:44
The clinical application of Roche Tiragolumab injection was accepted again by the CDE
10
PART10 | 06:24
Pfizer and BioNTech applied to the FDA for EUAof OmicronBA.4/BA.5-adapted bivalent COVID-19 mRNA vaccine for individuals 12 years of age and older
11
PART11 | 06:52
MinervaNeurosciences submitted an NDA for roluperidone to the FDA for the treatment of negative symptoms in patients with schizophrenia
12
PART12 | 07:11
The EC had approved Gilead's lenacapavir (brand name: Sunlenca) injection and tablets
13
PART13 | 07:37
The EC approved the conditional marketing of BioMarin's Roctavian gene therapy
14
PART14 | 08:11
The EC approved Johnson & Johnson's Teclistamab as a monotherapy for the treatment of adult patients with RRMM
15
PART15 | 08:43
The clinical trials of AstraZeneca/Ionis AZD8233 injection had been initiated in China
16
PART16 | 09:09
Apellis announced key results from two Phase III trials of its targeted complement C3 therapy pegcetacoplan
17
PART17 | 09:36
Novartis decided to temporarily suspend the ongoing Phase IIb clinical study evaluating its experimental Huntington's disease drug branaplam
18
PART18 | 10:05
Hansoh Pharmaceutical Group's wholly-owned subsidiary entered into an exclusive licensing and co-development agreement with GHDDI
19
PART19 | 10:48
Novartis announced its intention to separate its generic drug and biosimilar division into a newly listed independent operating company
20
PART20 | 11:24
The EU issues GMP Annex 1 final revision for sterile drug products
You can listen and/or download the episode on Podbean, or directly through iTunes, GooglePlay, Amazon Music and Samsung Podcasts. You can also subscribe our podcast by RSS feed, please copy the full URL below.
RSS Feed:
https://feed.podbean.com/PharmaSources/feed.xml
Copy Feed
Full Transcript

Drug Review

 

NMPA – Marketing

[Application]

1. On August 23, the CDE official website revealed that the marketing application for the new indication of BeiGene Tislelizumab (brand name: Baizean) was accepted by the NMPA. It is speculated that the new indication is the combination chemotherapy for patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). This is the 11th indication of the product declared for marketing in China, nine indications of which had been approved for marketing in the past.

 

NMPA – Clinical Trials

[Approval]

2. On August 22, the CDE official website revealed that the clinical trial application for Ascletis’ASC10 was approved. ASC10 is a COVID-19 oral candidate drug polymerase (RdRp) inhibitor developed independently by Ascletis, with a new and differentiated chemical structure compared to its single prodrug, molnupiravir. On August 3, ASC10 was approved by the FDA for a Phase Ib clinical trial in patients with mild to moderate COVID-19.

 

3. On August 22, Shanghai Pharma announced that its B013 injection was approved by the NMPA for Phase II clinical trials. The indications are the first-line treatment of locally advanced or metastatic triple-negative breast cancer. B013 injection is a novel human recombinant monoclonal antibody product. Shanghai Pharma entered into a license agreement with Oncternal and received exclusive rights in Greater China in September 2018.

 

4. On August 23, the CDE revealed that the fourth-generation EGFR inhibitor of Qilu Pharmaceutical, QLH11811, was approved for clinical use. Its indication is advanced NSCLC with EGFR and other driver gene abnormalities. QLH11811 shows better activity than the third-generation inhibitor, osimertinib, in the wild-type EGFR, the activating mutation ex19del, and the multiple combinatorial resistance mutations, and especially has the highest activity against the L858R/C797S combinational mutation (IC50=0.32nM). There have been nine EGFR inhibitors targeting the C797S mutation in the clinical stage worldwide.

 

5. On August 24, the anti-CD112R monoclonal antibody injection (project code: JS009) independently developed by Junshi Biosciences was approved by the CDE for clinical trials to treat advanced solid tumors. JS009 is a recombinant humanized IgG4 monoclonal antibody targeting CD112R. No product targeting CD112R has been approved for marketing in China or abroad by now.

 

6. On August 24, Keymed Biosciences Inc. and InnoCare Pharma announced that CM369, a monoclonal antibody targeting CCR8 developed by their joint venture, Tiannuo Jiancheng, was approved for clinical trials. Its indication is advanced solid tumors. There are 21 CCR8 monoclonal antibody products in development worldwide, of which six have entered the clinical development stage.

 

[Application]

7. On August 22, the CDE official website revealed that the clinical trial application of Akeso, Inc.’s AK129 injection was accepted for the treatment of cancers. AK129 is a bispecific antibody targeting human PD-1 and LAG3 developed by Akeso, Inc. Preclinical research has shown that AK129 has superior antigen binding properties to effectively block the PD-1/LAG-3 signaling pathway, and it can also promote the IL-2 and IFN-γ production in PBMC. Currently, the PD-1/LAG3 bispecific antibodies of EpimAb Biotherapeutics, Innovent, Zai Lab, and Roche have all entered the clinical stage in China.

 

8. On August 23, the clinical trial application of the MVA-BNRSV vaccine, jointly developed by BavarianNordic and Nuance, was accepted for the prevention of respiratory syncytial virus (RSV) infection. MVA-BNRSV has been granted the breakthrough therapy designation (BTD) by the FDA.

 

9. On August 24, the CDE announced that the clinical application of Roche Tiragolumab injection was accepted again. Eight clinical trials of Tiragolumab, a TIGIT monoclonal antibody, have been registered in China, including one Phase I, one Phase II, two Phase Ib/II, and four Phase III clinical trials. The proposed indications are NSCLC, extensive-stage small cell lung cancer, esophageal squamous cell carcinoma, gastric cancer, liver cancer, etc.

 

FDA - Marketing

[Application]

10. On August 22, Pfizer and BioNTech announced that they had applied to the FDA for emergency use authorization (EUA) of OmicronBA.4/BA.5-adapted bivalent COVID-19 mRNA vaccine for individuals 12 years of age and older. The bivalent vaccine contains mRNA encoding the original SARS-CoV-2 spike protein and mRNA encoding the spike protein of OmicronBA.4/BA.5 variants.

 

11. On August 22, MinervaNeurosciences announced that it had submitted a new drug application (NDA) for roluperidone to the FDA for the treatment of negative symptoms in patients with schizophrenia. Roluperidone is a 5-HT2A and σ2 receptor antagonist originally developed by Mitsubishi Tanabe.

 

EC - Marketing

[Approval]

12. On August 22, Gilead announced that the European Commission (EC) had approved lenacapavir (brand name: Sunlenca) injection and tablets for the treatment of multi-drug resistant HIV-1 infected patients who have received multiple prior treatments in combination with other antiretroviral drugs. Lenacapavir, a first-in-class long-acting HIV capsid inhibitor, is the only HIV therapeutic drug approved for marketing, which can be dosed twice per year.

 

13. On August 24, BioMarin announced that the European Commission (EC) approved the conditional marketing of Roctavian (Valoctocogeneroxaparvovec) gene therapy. It is for the treatment of adult patients with severe hemophilia A without coagulation factor VIII inhibitors and adeno-associated virus 5 (AAV5) antibodies in their bodies. Roctavian is the first approved gene therapy for the treatment of hemophilia A patients. In addition, the EU has maintained the orphan drug designation for the therapy and granted a 10-year market exclusivity.

 

14. On August 24, Johnson & Johnson announced that the European Commission (EC) has approved Teclistamab (brand name: TECVAYLI) as a monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). They have received at least three prior therapies, including immunomodulators, proteasome inhibitors, and an anti-CD38 antibody, but the disease has continued to progress since their last treatment. This is the first BCMA/CD3 bispecific antibody approved for marketing worldwide.

 


R&D

 

Clinical trials launching

15. On August 24, the drug clinical trial registration and information publicity platform of CDE indicated that the clinical trials of AstraZeneca/Ionis AZD8233 injection had been initiated in China. AZD8233 (also known as ION449) is a GalNAc (N-acetylgalactosamine) ASO drug for targeted inhibition of PCSK9 mRNA translation and protein synthesis in hepatocytes.

 

Clinical data release

16. On August 24, Apellis announced key results from two Phase III trials (DERBY and OAKS) of its targeted complement C3 therapy pegcetacoplan. The data indicated that pegcetacoplan did not provide any benefit in terms of visual function improvement in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at the 24th month’s treatment and did not meet its key secondary endpoint, but its effects increased over time.

 

17. On August 24, Novartis announced that it had decided to temporarily suspend the ongoing Phase IIb clinical study evaluating its experimental Huntington's disease (HD) drug branaplam, citing possible side effects. During the regular data review process, the independent Data Monitoring Committee (DMC) of the VIBRANT-HD research recommended the suspension of dosing due to early signs of side effects reported in treated subjects.

 


Business

 

18. On August 22, Hansoh Pharmaceutical Group announced that its wholly owned subsidiary had entered into an exclusive licensing and co-development agreement with Global Health Drug Discovery Institute (GHDDI). Pursuant to the licensing agreement, Henson Pharmaceuticals will obtain exclusive worldwide rights to develop, manufacture, and commercialize the anti-novel coronavirus new drug candidate GDI4405. The total amount of business is up to RMB1.692 billion. The candidate is an oral small molecule SARS-CoV-2 3CL protease inhibitor that exhibits high potent antiviral activity on SARS-CoV-2 Delta and Omicron variants.

 

19. On August 25, Novartis announced its intention to separate its generic drug and biosimilar division, Sandoz, into a newly listed independent operating company, with the process expected to be completed in the second half of the next year. Novartis indicated that the separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the No.1 European generics company and a global leader in biosimilars.

 


Policy

 

20. On August 25, the EU’s final revision of its good manufacturing practice (GMP) Annex 1 for sterile drug was officially released. The new Annex contains 59 pages, which will take effect within 1 year from the date of publication, i.e., no later than 25 August 2023, except for section 8.123, which will take effect one year later on 25 August 2024.

Read More
The First Domestically Developed JAK Inhibitor Ivarmacitinib is Expected to Be First Marketed in China for Autoimmune System Diseases
EPISODE 30 |  16 MIN  |  22 Nov. 2022
#Drug Review #R&D #Business
The online platform for CPHI & PMEC China is fully live now! The online event will be live for 54 days to help you connect for an extended period of time. Looking back on this week's pharma news, BeiGene's new indication for Zanubrutinib was approved in the EU while TopAlliance submitted a marketing application for the anti-PD-1 monoclonal antibody Toripalimab in the EU. The most noteworthy in the R&D section is Hengrui's JAK inhibitor Phase III clinical success, making it be expected to become the first product made in China in the field of autoimmune system diseases.
Play
NMPA Nod Gives YL-Pharma First Highly Selective PI3Kδ Inhibitor Marketing Approval in China
EPISODE 29 |  14 MIN  |  15 Nov. 2022
#Drug Review #R&D #Business
This week, the first highly selective PI3Kδ inhibitor in China, linperlisib of YL-Pharma, was approved for marketing. Multiple positive results have been released from several clinical trials, but GSK announced that the Phase III superiority trial of its BCMA ADC combined with pomalidomide in the treatment of relapsed or refractory multiple myeloma, did not meet its primary endpoint of progression-free survival (PFS). Jumpcan Pharmaceutical entered into a cooperation agreement with Newsoara and obtained the development rights of two innovative drugs.
Play
The Marketing Approval of Luye Pharma’s First-in-class Anti-depressant Drug in China
EPISODE 28 |  14 MIN  |  08 Nov. 2022
#Drug Review #R&D #Business
This week, Toludesvenlafaxine Hydrochloride Extended-Release Tablets, a kind of first-in-class anti-depressant drug developed by the Chinese company Luye Pharma, was approved for marketing. In terms of R&D, the phase III clinical research of PCSK9 Monoclonal Antibody developed by Akeso met the endpoints and was planned to apply for marketing. In terms of business, SonnetBio and Janssen, a subsidiary of Johnson & Johnson, reached a cooperation agreement on three candidate products.
Play
The Marketing Declaration of HAISCO's Novel Analgesic for Diabetic Peripheral Neuralgia Treatment
EPISODE 27 |  13 MIN  |  01 Nov. 2022
#Drug Review #R&D #Business #Listing #COVID-19
The marketing application of HAISCO's first-in-class HSK16149 Capsule was submitted, presumably for the treatment of diabetic peripheral neuralgia. While in the global markets, Simcere Pharmaceutical's SIM0237 had been approved for clinical use in the United States for the treatment of locally advanced unresectable or metastatic solid tumors. In terms of R&D, several clinical trials achieved positive results, while Alpine Immune terminated two clinical trials of davoceticept due to the death of patients.
Play
Subscribe Now